Kainova Therapeutics announced positive topline results from the Phase I EPRAD study of DT-9081, an oral EP4 receptor antagonist, on March 10, 2026. 1 2 The study in patients with advanced, recurrent, and metastatic solid tumors met all primary objectives, showing favorable safety with no dose-limiting toxicities, robust PK/PD with dose-proportional exposure, sustained EP4 receptor engagement, and early anti-tumor activity. 1 2 Conducted at four sites in France and Belgium; full details on clinicaltrials.gov NCT05582850. 1 2 DT-9081 aims to reverse PGE2-mediated immunosuppression to improve responses to immune checkpoint inhibitors; preclinical data supports use in cancers like triple-negative breast, sarcoma, and colorectal. 1 4 Quotes from PI Jean-Pascal Machiels, CMO Jean-Marie Cuillerot, and CEO Sean A. MacDonald highlight validation of EP4 antagonism for overcoming immunotherapy resistance. 1 2 Sources: 1. https://www.globenewswire.com/news-release/2026/03/10/3252479/0...
- Get link
- X
- Other Apps